Abstract:
Background. Glomerular pathology involves complex molecular mechanisms, and the
metabolic dysfunction of sphingolipids and cholesterol plays a key role in the initiation and
progression of glomerular lesions, contributing to the alteration of podocyte structure and
function, inducing inflammation and sclerosis.
Objective(s). The impact of disrupted sphingolipid metabolism (ceramides and
sphingomyelin) and cholesterol in glomerular diseases, as well as the identification of
potential targets for therapeutic intervention.
Materials and methods. A critical review of literature (2010–2024) was conducted,
including experimental, observational studies, and meta-analyses on lipid levels,
sphingolipid biosynthesis enzymes, and cholesterol transport in conditions like focal
segmental glomerulosclerosis (FSGS), diabetic nephropathy, and membranous
glomerulonephritis.
Results. Studies show that abnormal accumulation of ceramides and cholesterol in
podocytes is associated with cell apoptosis, mitochondrial dysfunction, and loss of
glomerular filtration function. Aberrant expression of enzymes in the sphingosine-1-
phosphate pathway or dysfunction of cholesterol transporters (ABCA1, NPC1) worsens
inflammatory and fibrogenic processes. These changes contribute to the initiation and
progression of glomerular diseases by impairing the integrity of the filtration barrier,
amplifying oxidative stress, inducing local profibrotic responses, disrupting cellular
homeostasis, and triggering persistent maladaptive mechanisms.
Conclusion(s). Dysregulation of lipid metabolism is a major and complex pathogenic factor
in glomerular diseases. Pharmacological interventions that modulate the metabolic
pathways of sphingolipids or cholesterol transport may represent promising and effective
strategies for glomerular protection.
